NICE is considering whether sufficient new evidence has emerged to undertake a full update of TA854 Esketamine for treatment-resistant depression. The review proposal has been sent to stakeholders, who have 28 days to comment on the review proposal.
Closing date for comments: 5pm, 31 October 2023
This page was last updated: